Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
University Federico II of Napoli, Department of Medical Oncology, Endocrinology and Oncology , Naples , Italy.Expert Opinion on Pharmacotherapy (Impact Factor: 2.86). 03/2012; DOI: 10.1517/14656566.2012.668097
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.